- Home
- MRNS vs NTIP Comparison
MRNS vs NTIP Comparison
Compare MRNS & NTIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRNS
- NTIP
- Stock Information
- Founded
- MRNS 2003
- NTIP 1990
- Country
- MRNS United States
- NTIP United States
- Employees
- MRNS N/A
- NTIP N/A
- Industry
- MRNS Biotechnology: Pharmaceutical Preparations
- NTIP Multi-Sector Companies
- Sector
- MRNS Health Care
- NTIP Miscellaneous
- Exchange
- MRNS Nasdaq
- NTIP Nasdaq
- Market Cap
- MRNS 29.9M
- NTIP 32.9M
- IPO Year
- MRNS 2014
- NTIP 1998
- Fundamental
- Price
- MRNS $0.54
- NTIP $1.38
- Analyst Decision
- MRNS Buy
- NTIP
- Analyst Count
- MRNS 12
- NTIP 0
- Target Price
- MRNS $4.28
- NTIP N/A
- AVG Volume (30 Days)
- MRNS 3.2M
- NTIP 62.9K
- Earning Date
- MRNS 03-04-2025
- NTIP 03-07-2025
- Dividend Yield
- MRNS N/A
- NTIP 7.25%
- EPS Growth
- MRNS N/A
- NTIP N/A
- EPS
- MRNS N/A
- NTIP N/A
- Revenue
- MRNS $31,466,000.00
- NTIP $1,881,000.00
- Revenue This Year
- MRNS $14.97
- NTIP N/A
- Revenue Next Year
- MRNS $57.65
- NTIP N/A
- P/E Ratio
- MRNS N/A
- NTIP N/A
- Revenue Growth
- MRNS 1.63
- NTIP 129.39
- 52 Week Low
- MRNS $0.22
- NTIP $1.22
- 52 Week High
- MRNS $10.50
- NTIP $2.25
- Technical
- Relative Strength Index (RSI)
- MRNS 70.29
- NTIP 51.53
- Support Level
- MRNS $0.54
- NTIP $1.33
- Resistance Level
- MRNS $0.56
- NTIP $1.47
- Average True Range (ATR)
- MRNS 0.02
- NTIP 0.07
- MACD
- MRNS 0.01
- NTIP -0.00
- Stochastic Oscillator
- MRNS 93.71
- NTIP 43.75
About MRNS Marinus Pharmaceuticals Inc.
Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.
About NTIP Network-1 Technologies Inc.
Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property rights. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.